Trgovina Jazz Pharmaceuticals plc - JAZZ CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Razmik | 0.71 | ||||||||
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.024068% | ||||||||
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.001846% | ||||||||
Čas nočne pristojbine | 21:00 (UTC) | ||||||||
Min. tržena količina | 1 | ||||||||
Valuta | USD | ||||||||
Kritje | 20% | ||||||||
Borza | United States of America | ||||||||
Provizija na trgovanje | 0% |
*Information provided by Capital.com
Jazz Pharmaceuticals PLC ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Predhodno. Zapri* | 136.98 |
Odpri* | 135.87 |
Enoletna sprememba* | -14.19% |
Dnevni razpon* | 135.37 - 141.82 |
Razpon 52 wk | 125.36-169.98 |
Povprečni obseg (10 dni) | 506.92K |
Povprečni obseg (3 meseci) | 10.66M |
Tržna kapitalizacija | 8.95B |
Razmerje P/E | -100.00K |
Število delnic v obtoku | 63.33M |
Prihodki | 3.66B |
EPS | -3.56 |
Dividenda (donosnost v %) | N/A |
Beta | 0.74 |
Datum naslednjega zaslužka | N/A |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 141.19 | 4.00 | 2.92% | 137.19 | 141.96 | 135.30 |
Mar 23, 2023 | 136.98 | -0.95 | -0.69% | 137.93 | 139.60 | 135.77 |
Mar 22, 2023 | 138.43 | -0.44 | -0.32% | 138.87 | 141.33 | 137.81 |
Mar 21, 2023 | 139.49 | 2.60 | 1.90% | 136.89 | 140.57 | 136.89 |
Mar 20, 2023 | 137.51 | 2.36 | 1.75% | 135.15 | 138.33 | 133.89 |
Mar 17, 2023 | 134.67 | -1.47 | -1.08% | 136.14 | 136.50 | 133.87 |
Mar 16, 2023 | 136.64 | 4.04 | 3.05% | 132.60 | 137.38 | 131.42 |
Mar 15, 2023 | 134.38 | 2.42 | 1.83% | 131.96 | 135.30 | 131.47 |
Mar 14, 2023 | 134.93 | 1.52 | 1.14% | 133.41 | 137.77 | 133.40 |
Mar 13, 2023 | 133.93 | 1.92 | 1.45% | 132.01 | 136.41 | 131.23 |
Mar 10, 2023 | 133.88 | -2.03 | -1.49% | 135.91 | 136.70 | 132.24 |
Mar 9, 2023 | 137.25 | -1.92 | -1.38% | 139.17 | 139.95 | 136.28 |
Mar 8, 2023 | 139.31 | 2.15 | 1.57% | 137.16 | 140.62 | 137.16 |
Mar 7, 2023 | 138.50 | -1.29 | -0.92% | 139.79 | 140.95 | 136.53 |
Mar 6, 2023 | 142.26 | -2.62 | -1.81% | 144.88 | 145.48 | 141.72 |
Mar 3, 2023 | 145.54 | 2.33 | 1.63% | 143.21 | 146.93 | 143.21 |
Mar 2, 2023 | 143.61 | 3.16 | 2.25% | 140.45 | 145.52 | 138.85 |
Mar 1, 2023 | 139.97 | 1.99 | 1.44% | 137.98 | 142.13 | 137.93 |
Feb 28, 2023 | 139.86 | -0.62 | -0.44% | 140.48 | 142.22 | 139.30 |
Feb 27, 2023 | 140.83 | -1.76 | -1.23% | 142.59 | 144.65 | 140.83 |
Jazz Pharmaceuticals plc Events
Čas (UTC) (UTC) | Država | Dogodek |
---|---|---|
No events scheduled |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Skupni prihodki | 3659.37 | 3094.24 | 2363.57 | 2161.76 | 1890.92 |
Prihodki | 3659.37 | 3094.24 | 2363.57 | 2161.76 | 1890.92 |
Celotni stroški prihodkov | 540.517 | 440.76 | 148.917 | 127.93 | 121.544 |
Bruto dobiček | 3118.86 | 2653.48 | 2214.65 | 2033.83 | 1769.38 |
Celotni odhodki iz poslovanja | 3724.9 | 2923.96 | 1990.59 | 1629.39 | 1277.51 |
Celotna prodaja/splošni/upravni stroški Odhodki | 1376.17 | 1222.68 | 854.233 | 736.942 | 683.53 |
Raziskave in razvoj | 1034.6 | 505.748 | 586.625 | 409.701 | 226.616 |
Depreciation / Amortization | 599.169 | 525.769 | 259.58 | 354.814 | 201.498 |
Nenavadni odhodki (prihodki) | 174.448 | 229 | 141.239 | 0 | 44.321 |
Prihodki iz poslovanja | -65.528 | 170.278 | 372.973 | 532.374 | 613.413 |
Prihodki (odhodki) od obresti, neto Neoperativni | -307.256 | -283.116 | -97.878 | -78.072 | -86.153 |
Čisti dobiček pred obdavčitvijo | -372.784 | -112.838 | 275.095 | 454.302 | 527.26 |
Čisti dobiček po davkih | -214.139 | -328.954 | 241.578 | 527.456 | 447.091 |
Manjšinski delež | |||||
Čisti dobiček pred dodatnimi postavkami | -224.06 | -329.668 | 238.616 | 523.367 | 447.091 |
Čisti dobiček | -224.06 | -329.668 | 238.616 | 523.367 | 447.098 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -224.06 | -329.668 | 238.616 | 523.367 | 447.091 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -224.06 | -329.668 | 238.616 | 523.367 | 447.098 |
Prilagoditev za redčenje | 0 | ||||
Popravljen čisti dobiček | -224.06 | -329.668 | 238.616 | 523.367 | 447.098 |
Popravljene ponderirane povprečne delnice | 62.539 | 59.694 | 56.517 | 57.55 | 61.221 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -3.58272 | -5.52263 | 4.22202 | 9.09413 | 7.30289 |
Popravljen normalizirani dobiček na enoto čistega dobička | -1.7696 | -3.02908 | 6.4166 | 9.09413 | 7.91677 |
Skupaj izredne postavke | 0 | 0.0075 | |||
Equity In Affiliates | -9.921 | -0.714 | -2.962 | -4.089 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Skupni prihodki | 972.123 | 940.652 | 932.878 | 813.721 | 896.731 |
Prihodki | 972.123 | 940.652 | 932.878 | 813.721 | 896.731 |
Celotni stroški prihodkov | 167.364 | 133.661 | 124.208 | 115.284 | 136.153 |
Bruto dobiček | 804.759 | 806.991 | 808.67 | 698.437 | 760.578 |
Celotni odhodki iz poslovanja | 1235.51 | 915.889 | 847.332 | 726.172 | 847.351 |
Celotna prodaja/splošni/upravni stroški Odhodki | 383.203 | 317.678 | 325.673 | 308.813 | 254.862 |
Raziskave in razvoj | 547.555 | 148.87 | 208.195 | 129.981 | 155.443 |
Depreciation / Amortization | 137.387 | 141.232 | 148.456 | 172.094 | 157.293 |
Nenavadni odhodki (prihodki) | 0 | 174.448 | 40.8 | 143.6 | |
Prihodki iz poslovanja | -263.386 | 24.763 | 85.546 | 87.549 | 49.38 |
Prihodki (odhodki) od obresti, neto Neoperativni | -76.607 | -84.893 | -64.532 | -81.224 | -94.21 |
Čisti dobiček pred obdavčitvijo | -339.993 | -60.13 | 21.014 | 6.325 | -44.83 |
Čisti dobiček po davkih | -239.951 | -17.103 | 37.126 | 5.789 | -32.363 |
Equity In Affiliates | -0.773 | -2.545 | -2.461 | -4.142 | -2.988 |
Čisti dobiček pred dodatnimi postavkami | -240.724 | -19.648 | 34.665 | 1.647 | -35.351 |
Čisti dobiček | -240.724 | -19.648 | 34.665 | 1.647 | -35.351 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -240.724 | -19.648 | 34.665 | 1.647 | -35.351 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -240.724 | -19.648 | 34.665 | 1.647 | -35.351 |
Popravljen čisti dobiček | -240.724 | -19.648 | 34.665 | 1.647 | -35.351 |
Popravljene ponderirane povprečne delnice | 63.061 | 62.785 | 63.431 | 62.907 | 61.524 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -3.81732 | -0.31294 | 0.5465 | 0.02618 | -0.57459 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Popravljen normalizirani dobiček na enoto čistega dobička | -3.81732 | 1.49308 | 0.96459 | 0.02618 | 0.94254 |
- Letni
- Četrtletno
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 2611.33 | 2839.57 | 1630.27 | 1234.01 | 968.277 |
Denarna sredstva in kratkoročne naložbe | 591.448 | 2132.77 | 1077.34 | 824.622 | 601.035 |
Denarna sredstva in ustrezniki | 386.035 | ||||
Kratkoročne naložbe | 80.701 | 1615.65 | 744.172 | 609.016 | 215 |
Celotne terjatve, neto | 563.36 | 396.49 | 355.987 | 263.838 | 224.129 |
Accounts Receivable - Trade, Net | 563.36 | 396.49 | 355.987 | 263.838 | 224.129 |
Total Inventory | 1072.72 | 95.396 | 78.608 | 52.956 | 43.245 |
Prepaid Expenses | 131.413 | 62.422 | 39.434 | 25.017 | 23.182 |
Other Current Assets, Total | 252.392 | 152.491 | 78.895 | 67.572 | 76.686 |
Total Assets | 12298.6 | 6535.9 | 5538.9 | 5203.49 | 5123.67 |
Property/Plant/Equipment, Total - Net | 343.423 | 257.104 | 270.891 | 200.358 | 170.08 |
Property/Plant/Equipment, Total - Gross | 428.794 | 324.692 | 326.148 | 249.966 | 211.283 |
Accumulated Depreciation, Total | -85.371 | -67.588 | -55.257 | -49.608 | -41.203 |
Goodwill, Net | 1827.61 | 958.303 | 920.018 | 927.63 | 947.537 |
Intangibles, Net | 7152.33 | 2195.05 | 2440.98 | 2731.33 | 2979.13 |
Other Long Term Assets, Total | 363.945 | 285.875 | 276.743 | 110.164 | 58.651 |
Total Current Liabilities | 809.303 | 653.745 | 364.49 | 345.487 | 293.947 |
Accounts Payable | 100.298 | 26.945 | 47.545 | 40.602 | 24.368 |
Accrued Expenses | 647.479 | 349.107 | 266.836 | 263.427 | 198.779 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 31.406 | 246.322 | 33.387 | 33.387 | 40.605 |
Other Current Liabilities, Total | 30.12 | 31.371 | 16.722 | 8.071 | 30.195 |
Total Liabilities | 8333.45 | 2876.16 | 2427.92 | 2446.07 | 2410.57 |
Total Long Term Debt | 6025.21 | 1848.52 | 1573.87 | 1563.03 | 1540.43 |
Long Term Debt | 6018.94 | 1848.52 | 1573.87 | 1563.03 | 1540.43 |
Deferred Income Tax | 1300.54 | 130.397 | 224.095 | 309.097 | 383.472 |
Other Liabilities, Total | 198.392 | 243.498 | 265.461 | 228.46 | 192.723 |
Total Equity | 3965.19 | 3659.75 | 3110.98 | 2757.42 | 2713.1 |
Common Stock | 0.061 | 0.061 | 0.061 | 0.061 | 0.061 |
Additional Paid-In Capital | 3534.79 | 2633.67 | 2266.03 | 2113.63 | 1935.49 |
Retained Earnings (Accumulated Deficit) | 830.698 | 1160.37 | 1068.29 | 841.522 | 918.428 |
Other Equity, Total | -400.36 | -134.352 | -223.393 | -197.791 | -140.878 |
Total Liabilities & Shareholders’ Equity | 12298.6 | 6535.9 | 5538.9 | 5203.49 | 5123.67 |
Total Common Shares Outstanding | 61.633 | 56.171 | 56.14 | 57.504 | 59.898 |
Cash | 510.747 | 517.117 | 333.172 | 215.606 | |
Capital Lease Obligations | 6.269 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 2500.86 | 2611.33 | 2628.23 | 2953.96 | 3166.9 |
Denarna sredstva in kratkoročne naložbe | 490.835 | 591.448 | 671.78 | 891.4 | 2432.53 |
Cash | 410.125 | 510.747 | 436.082 | 586.527 | 851.856 |
Denarna sredstva in ustrezniki | 105.698 | 164.873 | 285.677 | ||
Kratkoročne naložbe | 80.71 | 80.701 | 130 | 140 | 1295 |
Celotne terjatve, neto | 572.392 | 563.36 | 499.023 | 506.66 | 413.976 |
Accounts Receivable - Trade, Net | 572.392 | 563.36 | 499.023 | 506.66 | 413.976 |
Total Inventory | 985.454 | 1072.72 | 1137.85 | 1251.26 | 115.475 |
Prepaid Expenses | 117.399 | 131.413 | 94.474 | 104.455 | 57.185 |
Other Current Assets, Total | 334.776 | 252.392 | 225.098 | 200.19 | 147.727 |
Total Assets | 11768.9 | 12298.6 | 12478.2 | 13213 | 6756.47 |
Property/Plant/Equipment, Total - Net | 341.044 | 343.423 | 344.634 | 426.32 | 249.601 |
Property/Plant/Equipment, Total - Gross | 433.74 | 428.794 | 423.23 | 503.279 | 319.59 |
Accumulated Depreciation, Total | -92.696 | -85.371 | -78.596 | -76.959 | -69.989 |
Goodwill, Net | 1782.44 | 1827.61 | 1849.55 | 1887.7 | 938.398 |
Intangibles, Net | 6783.06 | 7152.33 | 7282.58 | 7588.03 | 2108.05 |
Other Long Term Assets, Total | 361.516 | 363.945 | 373.166 | 356.981 | 293.529 |
Total Current Liabilities | 737.409 | 809.303 | 735.053 | 880.588 | 752.093 |
Accounts Payable | 73.336 | 100.298 | 63.815 | 64.826 | 77.738 |
Accrued Expenses | 596.292 | 647.479 | 572.82 | 543.22 | 361.359 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 31 | 31.406 | 31.402 | 248.967 | 248.613 |
Other Current Liabilities, Total | 36.781 | 30.12 | 67.016 | 23.575 | 64.383 |
Total Liabilities | 8160.43 | 8333.45 | 8539.67 | 9081.5 | 2958.78 |
Total Long Term Debt | 5992.87 | 6025.21 | 6253.65 | 6495.33 | 1853.03 |
Long Term Debt | 5992.87 | 6018.94 | 6247.29 | 6489.31 | 1853.03 |
Deferred Income Tax | 1222.08 | 1300.54 | 1329.18 | 1421.03 | 109.915 |
Other Liabilities, Total | 208.069 | 198.392 | 221.791 | 284.558 | 243.74 |
Total Equity | 3608.49 | 3965.19 | 3938.48 | 4131.49 | 3797.69 |
Common Stock | 0.061 | 0.061 | 0.061 | 0.061 | 0.061 |
Additional Paid-In Capital | 3239.33 | 3534.79 | 3469.88 | 3403.48 | 2694.86 |
Retained Earnings (Accumulated Deficit) | 959.819 | 830.698 | 866.049 | 918.882 | 1282.2 |
Other Equity, Total | -590.72 | -400.36 | -397.517 | -190.935 | -179.428 |
Total Liabilities & Shareholders’ Equity | 11768.9 | 12298.6 | 12478.2 | 13213 | 6756.47 |
Total Common Shares Outstanding | 62.244 | 61.633 | 61.38 | 61.115 | 56.873 |
Capital Lease Obligations | 6.269 | 6.36 | 6.015 |
- Letni
- Četrtletno
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Čisti prihodki/začetna postavka | -329.668 | 238.616 | 523.367 | 447.098 | 487.848 |
Denarna sredstva iz poslovanja | 778.507 | 899.648 | 776.401 | 798.904 | 693.087 |
Denarna sredstva iz poslovanja | 26.714 | 18.673 | 15.342 | 15.233 | 13.089 |
Amortization | 525.769 | 259.58 | 354.814 | 201.498 | 152.065 |
Deferred Taxes | 69.198 | -136.937 | -236.61 | -88.815 | -225.591 |
Nedenarne postavke | 326.944 | 617.519 | 283.72 | 200.604 | 238.91 |
Cash Taxes Paid | 271.217 | 226.823 | 183.61 | 164.217 | 174.124 |
Denarna sredstva Plačane obresti | 138.271 | 42.47 | 43.002 | 42.706 | 44.609 |
Spremembe v obratnem kapitalu | 159.55 | -97.803 | -164.232 | 23.286 | 26.766 |
Denarna sredstva pri naložbenju | -5212.14 | -1007.67 | -155.3 | -394.487 | -268.95 |
Kapitalski izdatki | -45.532 | -379.254 | -182.335 | -131.47 | -113.95 |
Celotne druge postavke denarnih tokov pri naložbenju | -5166.61 | -628.416 | 27.035 | -263.017 | -155 |
Denarna sredstva pri financiranju | 3970.52 | 528.073 | -293.745 | -479.13 | -409.111 |
Postavke denarnega toka pri financiranju | -35.602 | -16.877 | -16.739 | -23.078 | -15.435 |
Izdaja (odplačilo) delnic, neto | 135.261 | -46.856 | -243.619 | -430.335 | -66.975 |
Izdaja (odplačilo) dolga, neto | 3870.86 | 591.806 | -33.387 | -25.717 | -326.701 |
Učinki deviznih tečajev | -3.207 | 0.374 | 0.366 | -1.7 | 5.046 |
Neto sprememba denarnih sredstev | -466.321 | 420.425 | 327.722 | -76.413 | 20.072 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 1.647 | -329.668 | -294.317 | -241.484 | 121.832 |
Cash From Operating Activities | 208.979 | 778.507 | 600.752 | 326.692 | 284.997 |
Cash From Operating Activities | 7.617 | 26.714 | 19.387 | 11.614 | 4.779 |
Amortization | 172.094 | 525.769 | 368.476 | 208.672 | 68.192 |
Deferred Taxes | -45.339 | 69.198 | 96.593 | 171.587 | -19.11 |
Non-Cash Items | 52.802 | 326.944 | 237.062 | 140.276 | 62.712 |
Changes in Working Capital | 20.158 | 159.55 | 173.551 | 36.027 | 46.592 |
Cash From Investing Activities | -37.292 | -5212.14 | -5202.05 | -5175.24 | 737.132 |
Capital Expenditures | -37.292 | -45.532 | -35.565 | -9.346 | -2.168 |
Other Investing Cash Flow Items, Total | 0 | -5166.61 | -5166.49 | -5165.89 | 739.3 |
Cash From Financing Activities | -270.811 | 3970.52 | 4217.13 | 4682.31 | 18.276 |
Financing Cash Flow Items | -33.776 | -35.602 | -29.603 | -27.172 | -23.784 |
Issuance (Retirement) of Stock, Net | 21.729 | 135.261 | 117.111 | 102.289 | 50.407 |
Issuance (Retirement) of Debt, Net | -258.764 | 3870.86 | 4129.62 | 4607.19 | -8.347 |
Foreign Exchange Effects | -1.489 | -3.207 | -1.821 | -0.135 | -0.641 |
Net Change in Cash | -100.613 | -466.321 | -385.989 | -166.369 | 1039.76 |
Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.5026 | 6018102 | 159714 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 8.5003 | 5383363 | 164119 | 2022-12-31 | LOW |
JP Morgan Asset Management | Investment Advisor | 3.833 | 2427504 | -482182 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.6397 | 2305057 | 15476 | 2022-12-31 | LOW |
LSV Asset Management | Investment Advisor | 3.2462 | 2055894 | 294917 | 2022-12-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 3.0283 | 1917890 | -37592 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 2.0369 | 1290015 | -8494 | 2022-12-31 | HIGH |
Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 2.0093 | 1272499 | 27286 | 2022-12-31 | LOW |
Polaris Capital Management, LLC | Investment Advisor | 1.979 | 1253360 | -217100 | 2022-12-31 | LOW |
Mulligan (Seamus C) | Individual Investor | 1.8357 | 1162554 | 4500 | 2023-03-04 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.7455 | 1105435 | 102953 | 2022-12-31 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.7319 | 1096843 | -142057 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.4789 | 936615 | 61364 | 2022-12-31 | LOW |
Deep Track Capital LP | Hedge Fund | 1.3793 | 873553 | 12553 | 2022-12-31 | MED |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.3225 | 837562 | -115228 | 2022-12-31 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 1.2796 | 810398 | -161157 | 2022-12-31 | LOW |
Bellevue Asset Management AG | Investment Advisor | 1.1947 | 756636 | -67203 | 2022-12-31 | LOW |
Avidity Partners Management LP | Hedge Fund | 1.1488 | 727541 | 409241 | 2022-12-31 | HIGH |
Arrowstreet Capital, Limited Partnership | Investment Advisor/Hedge Fund | 1.0808 | 684517 | 182721 | 2022-12-31 | MED |
Citadel Advisors LLC | Hedge Fund | 0.9924 | 628488 | 628488 | 2022-12-31 | HIGH |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group500K+
Borzni posredniki
92K+
Aktivne stranke mesečno
$53M+
Mesečni obseg naložb
$30M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Jazz Pharma Company profile
O družbi Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Public Limited Company je biofarmacevtsko podjetje. Osredotoča se na razvoj in trženje izdelkov, ki zadovoljujejo neizpolnjene medicinske potrebe. Družba ima raznovrsten portfelj izdelkov in kandidatov za izdelke s poudarkom na področjih spanja in hematologije/onkologije. Glavni tržni izdelki družbe vključujejo Xyrem (peroralna raztopina natrijevega oksibata) za zdravljenje katapleksije in prekomerne dnevne zaspanosti pri bolnikih z narkolepsijo; Erwinaze za zdravljenje akutne limfoblastne levkemije (ALL) in Defitelio (defibrotid) za zdravljenje hude jetrne venookluzivne bolezni (VOD). Družba trži tudi zdravilo Prialt, intratekalno infuzijo zikonotida, ki ga je FDA odobrila za zdravljenje hude kronične bolečine pri bolnikih, pri katerih je intratekalno zdravljenje upravičeno in ki ne prenašajo drugega zdravljenja, kot so sistemski analgetiki, dodatne terapije ali intratekalni morfin, ali so nanj odporni.
Industry: | Pharmaceuticals (NEC) |
Fifth Fl
Waterloo Exchange
DUBLIN
DUBLIN 4
IE
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 500.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com